131 related articles for article (PubMed ID: 30396310)
21. Genistein modulates oxidative stress in breast cancer cell lines according to ERα/ERβ ratio: effects on mitochondrial functionality, sirtuins, uncoupling protein 2 and antioxidant enzymes.
Nadal-Serrano M; Pons DG; Sastre-Serra J; Blanquer-Rosselló Mdel M; Roca P; Oliver J
Int J Biochem Cell Biol; 2013 Sep; 45(9):2045-51. PubMed ID: 23871935
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target.
Skliris GP; Leygue E; Watson PH; Murphy LC
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):1-10. PubMed ID: 18243688
[TBL] [Abstract][Full Text] [Related]
23. The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT.
Wang X; Yang Z; Zhang H; Ding L; Li X; Zhu C; Zheng Y; Ye Q
Biochim Biophys Acta; 2008 Jun; 1783(6):1220-8. PubMed ID: 18302941
[TBL] [Abstract][Full Text] [Related]
24. In silico Molecular Modelling of Selected Natural Ligands and their Binding Features with Estrogen Receptor Alpha.
Maruthanila VL; Elancheran R; Roy NK; Bhattacharya A; Kunnumakkara AB; Kabilan S; Kotoky J
Curr Comput Aided Drug Des; 2019; 15(1):89-96. PubMed ID: 30306879
[TBL] [Abstract][Full Text] [Related]
25. Multitargeted Molecular Docking Study of Natural-Derived Alkaloids on Breast Cancer Pathway Components.
Singla R; Jaitak V
Curr Comput Aided Drug Des; 2017 Nov; 13(4):294-302. PubMed ID: 28382865
[TBL] [Abstract][Full Text] [Related]
26. Antileukemic effect of zerumbone-loaded nanostructured lipid carrier in WEHI-3B cell-induced murine leukemia model.
Rahman HS; Rasedee A; How CW; Zeenathul NA; Chartrand MS; Yeap SK; Abdul AB; Tan SW; Othman HH; Ajdari Z; Namvar F; Arulselvan P; Fakurazi S; Mehrbod P; Daneshvar N; Begum H
Int J Nanomedicine; 2015; 10():1649-66. PubMed ID: 25767386
[TBL] [Abstract][Full Text] [Related]
27. Zerumbone modulates CD1d expression and lipid antigen presentation pathway in breast cancer cells.
Shyanti RK; Sehrawat A; Singh SV; Mishra JPN; Singh RP
Toxicol In Vitro; 2017 Oct; 44():74-84. PubMed ID: 28633979
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of azaisoflavone analogs as phytoestrogen mimetics.
Gim HJ; Li H; Jung SR; Park YJ; Ryu JH; Chung KH; Jeon R
Eur J Med Chem; 2014 Oct; 85():107-18. PubMed ID: 25078314
[TBL] [Abstract][Full Text] [Related]
29. Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.
Lu W; Katzenellenbogen BS
Horm Cancer; 2017 Aug; 8(4):230-242. PubMed ID: 28577282
[TBL] [Abstract][Full Text] [Related]
30. Charge Density and Electrostatic Potential Study of 16α,17β-Estriol and the Binding of Estrogen Molecules to the Estrogen Receptors ERα and ERβ.
Zhurova EA; Zhurov VV; Kumaradhas P; Cenedese S; Pinkerton AA
J Phys Chem B; 2016 Sep; 120(34):8882-91. PubMed ID: 27504698
[TBL] [Abstract][Full Text] [Related]
31. Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells.
Kim S; Kil WH; Lee J; Oh SJ; Han J; Jeon M; Jung T; Lee SK; Bae SY; Lee HC; Lee JH; Yi HW; Kim SW; Nam SJ; Lee JE
Oncol Rep; 2014 Dec; 32(6):2666-72. PubMed ID: 25269647
[TBL] [Abstract][Full Text] [Related]
32. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
33. Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve η1-N, η2-N,O, η1-O, and η6 bonding modes, via a novel N-π rearrangement; relative binding affinities and computer docking studies of cis and trans-η6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERα and ERβ receptors, and growth inhibition to breast cancer cells.
Top S; Efremenko I; Rager MN; Vessières A; Yaswen P; Jaouen G; Fish RH
Inorg Chem; 2011 Jan; 50(1):271-84. PubMed ID: 21121684
[TBL] [Abstract][Full Text] [Related]
34. Identification of Breast Cancer Inhibitors Specific for G Protein-Coupled Estrogen Receptor (GPER)-Expressing Cells.
Aiello F; Carullo G; Giordano F; Spina E; Nigro A; Garofalo A; Tassini S; Costantino G; Vincetti P; Bruno A; Radi M
ChemMedChem; 2017 Aug; 12(16):1279-1285. PubMed ID: 28520140
[TBL] [Abstract][Full Text] [Related]
35. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.
Pons DG; Torrens-Mas M; Nadal-Serrano M; Sastre-Serra J; Roca P; Oliver J
Int J Biochem Cell Biol; 2015 Sep; 66():85-94. PubMed ID: 26232188
[TBL] [Abstract][Full Text] [Related]
36. In vitro ultramorphological assessment of apoptosis induced by zerumbone on (HeLa).
Abdel Wahab SI; Abdul AB; Alzubairi AS; Mohamed Elhassan M; Mohan S
J Biomed Biotechnol; 2009; 2009():769568. PubMed ID: 19343171
[TBL] [Abstract][Full Text] [Related]
37. Use of binding energy in comparative molecular field analysis of isoform selective estrogen receptor ligands.
Wolohan P; Reichert DE
J Mol Graph Model; 2004 Sep; 23(1):23-38. PubMed ID: 15331051
[TBL] [Abstract][Full Text] [Related]
38. New computational strategy to analyze the interactions of ERalpha and ERbeta with different ERE sequences.
Marabotti A; Colonna G; Facchiano A
J Comput Chem; 2007 Apr; 28(6):1031-41. PubMed ID: 17269124
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of binding and antagonism/downregulation of brilanestrant molecule in estrogen receptor-α via quantum mechanics/molecular mechanics, molecular dynamics and binding free energy calculations.
Chinnasamy K; Saravanan M; Poomani K
J Biomol Struct Dyn; 2020 Jan; 38(1):219-235. PubMed ID: 31038398
[TBL] [Abstract][Full Text] [Related]
40. Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain.
Ashtekar SS; Bhatia NM; Bhatia MS
Steroids; 2018 Mar; 131():14-22. PubMed ID: 29307843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
